Eton Pharmaceuticals (ETON) EBITDA (2018 - 2025)

Eton Pharmaceuticals has disclosed EBITDA across 8 years of filings, most recently posting $2.4 million for Q4 2025.

• EBITDA for Q4 2025 came in at $2.4 million, down 3.09% year-over-year; the trailing twelve-month figure through Dec 2025 was -$957000.0 (down 19.63% YoY), and the FY2025 annual result was -$957000.0, down 19.63% from the prior year.
• EBITDA came in at $2.4 million for Q4 2025 at Eton Pharmaceuticals, up from -$1.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $7.4 million in Q4 2022 to a low of -$5.8 million in Q3 2021.
• The 5-year median for EBITDA is -$1.1 million (2022), against an average of -$316900.0.
• Across the five-year window, EBITDA surged 465.3% in 2022 and sank 367.78% in 2025, its largest moves.
• Eton Pharmaceuticals' EBITDA stood at $1.3 million in 2021, then soared by 465.3% to $7.4 million in 2022, then plunged by 126.83% to -$2.0 million in 2023, then surged by 221.73% to $2.4 million in 2024, then decreased by 3.09% to $2.4 million in 2025.
• The last three EBITDA figures came in at $2.4 million (Q4 2025), -$1.4 million (Q3 2025), and -$1.5 million (Q2 2025), per Business Quant data.